#USA #San Diego #Viking Therapeutics #Biopharmaceutical #VK2735

Viking Therapeutics Unveils Fundraising Strategy

Viking Therapeutics, Inc. (Nasdaq: VKTX), a prominent player in the biopharmaceutical sector, has disclosed its intent to raise a substantial $400 million through separate public offerings. This fundraising initiative includes $200 million in common stock and $200 million in convertible senior notes, both aimed at bolstering the development of innovative therapies for obesity and metabolic disorders.

Key Offering Details

On September 23, 2026, the California-based firm announced its proposed offerings, set to take place subject to market conditions. Importantly, the company plans to provide underwriters a 30-day option to purchase an additional $30 million in common stock and a similar amount in notes, catering to potential over-allotments. Notably, the successful completion of one offering will not rely on the other, streamlining the fundraising process.

The convertible senior notes, which are set to mature in 2032, will be senior, unsecured obligations of Viking. They will accrue interest on a semi-annual basis. A unique feature of these notes is the holders’ option to convert them under specified circumstances, allowing for settlement in cash, stock, or a combination of both, depending on the company's discretion.

Redemption and Repurchase Conditions

Viking retains the right to redeem these notes, in whole or part, after October 22, 2029, as long as specific market conditions are met. Furthermore, in case of certain significant corporate changes, noteholders have the right to require Viking to repurchase their notes, ensuring protection for investors amidst potential disruptions.

The exact terms of the notes, including the interest rate and conversion rate, will be defined closer to the pricing of the offering.

Intended Use of Proceeds

Viking's strategic plans for the net proceeds from both the notes and common stock offerings are expansive. The company aims to advance clinical development and commercialization of its VK2735 program – a dual-receptor agonist developed for obesity treatment. They are also focused on furthering the clinical advancements of their VK3019 program and other general research and corporate needs. This dual approach emphasizes the company's commitment to addressing obesity through innovative, science-backed solutions.

The Biopharmaceutical Landscape

Viking Therapeutics stands out in the clinical-stage biopharmaceutical arena, concentrating on advanced therapies for metabolic and endocrine disorders. Their flagship product, VK2735, is currently under rigorous testing in Phase 3 studies, hailed for its ambitions to provide long-term weight management solutions. Alongside VK2735, the company is advancing additional programs tailored for obesity, metabolic diseases, and other critical health challenges.

Viking’s decision to seek additional funding aligns with its long-term vision for improving patients’ health outcomes, showcasing an enduring commitment to scientific ingenuity and comprehensive treatment strategies.

Conclusion

The unfolding initiatives by Viking Therapeutics illustrate a dynamic approach in the biopharmaceutical industry, balancing investment potential with the urgent need for effective obesity treatments. Investors are watching closely as these offerings progress, with the results poised to impact the clinical landscape significantly.

For more information on the offerings or to obtain the preliminary prospectus, interested parties can visit the SEC's website or reach out to Morgan Stanley or J.P. Morgan for enquiry specifics.

Forward-Looking Statements

Viking Therapeutics encourages potential investors to remain cognizant of the inherent risks associated with forward-looking statements concerning the offerings and their expectations regarding the outcomes and use of proceeds. As market conditions evolve, Viking pledges to maintain transparency, ensuring investors are informed throughout the process.